A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Third-Party Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Resource Type
- Source
- Transplantation and Cellular Therapy. 28:S220
- Subject
Transplantation Molecular Medicine Immunology and Allergy Cell Biology Hematology - Language
- ISSN
- 2666-6367